 WESTLAKE VILLAGE, Calif., Dec. 01, 2020 GLOBE NEWSWIRE -- Arcutis Biotherapeutics, Inc. Nasdaq: ARQT, a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced positive results for the Phase 2 long-term safety study evaluating ARQ-151 topical roflumilast cream 0.3 as a potential once-daily chronic topical treatment for plaque psoriasis. 